March 31st 2023
Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.
Mirvetuximab Soravtansine Associated with Fewer GI Toxicities Than Chemotherapy in Advanced Ovarian CancerOctober 18th 2022
An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.
Oncology Nurses Need Better Resources to Help Patients With Mental Health ProblemsOctober 4th 2022
Although oncology nurses are trained to show empathy and offer support, they lack the resources to adequately care for patients with acute mental health problems.
Niraparib, Olaparib, and Rucaparib No Longer Available for Patients with Heavily Pretreated, BRCA-Mutated Advanced Ovarian CancerOctober 2nd 2022
Following potential safety concerns with 3 PARP inhibitors, manufactures have voluntarily elected to withdraw the indications for patients with heavily pretreated patients with BRCA-mutated ovarian cancer.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for PatientsSeptember 28th 2022
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Intense-Modulated Radiation Therapy Reduces Chronic Diarrhea and Urinary Toxicity in Women With Cervical or Endometrial CancerSeptember 26th 2022
Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.
Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian CancerSeptember 19th 2022
Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Cytokine Release Syndrome and Neurotoxicity Emerge as Primary AEs of Interest With Solid Tumor T-Cell Receptor TherapySeptember 11th 2022
In the phase 1 SURPASS trial, 72% of patients with solid tumors developed any-grade cytokine release syndrome following an infusion of ADP-A2M4CD8. The median time to resolution was 5 days.
PARP Inhibitor Niraparib Shows Efficacy as Maintenance Treatment in Advanced Ovarian CancerJuly 29th 2022
Chinese patients with newly diagnosed advanced ovarian cancer whose disease responsed to first-line chemotherapy experienced significantly improved progression-free survival with niraparib.
ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical ImplementationJuly 27th 2022
In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.
Mirvetuximab Soravtansine Is Under Priority Review for FRα-High, Platinum-Resistant Ovarian CancerJuly 18th 2022
Mirvetuximab soravtansine (IMGN853) has been granted priority review by the FDA for the treatment of patients with FRα-high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.
Are Oncology Nurses Underutilized in Positively Affecting the Opioid Epidemic?July 7th 2022
Gretchen McNally PhD, ANP-BC, AOCNP, discusses the potential impact advanced practice providers and nurses could have in the opioid pandemic if the correct educational opportunities were available.